Search Results - "Ri, Masaki"

Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma by Ri, Masaki

“…Bortezomib (BTZ), a proteasome inhibitor, was initially reported as an inhibitor of the NF-κB pathway, which plays a critical role in the pathogenesis of…”
Get full text

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma by Tachita, Takuto, Kinoshita, Shiori, Ri, Masaki, Aoki, Sho, Asano, Arisa, Kanamori, Takashi, Yoshida, Takashi, Totani, Haruhito, Ito, Asahi, Kusumoto, Shigeru, Komatsu, Hirokazu, Yamagata, Kazufumi, Kubo, Kohmei, Tohkin, Masahiro, Fukuda, Shinsaku, Iida, Shinsuke

“…Cereblon (CRBN) is a target for immunomodulatory drugs. This study investigated the prognostic value of the expression of CRBN‐pathway genes on the clinical…”
Get full text

Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries by Suzuki, Takayoshi, Ota, Yosuke, Ri, Masaki, Bando, Masashige, Gotoh, Aogu, Itoh, Yukihiro, Tsumoto, Hiroki, Tatum, Prima R, Mizukami, Tamio, Nakagawa, Hidehiko, Iida, Shinsuke, Ueda, Ryuzo, Shirahige, Katsuhiko, Miyata, Naoki

“…To find HDAC8-selective inhibitors, we designed a library of HDAC inhibitor candidates, each containing a zinc-binding group that coordinates with the…”
Get full text

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma by Maekawa, Keiko, Ri, Masaki, Nakajima, Miki, Sekine, Akihiro, Ueda, Ryuzo, Tohkin, Masahiro, Miyata, Naoki, Saito, Yoshiro, Iida, Shinsuke

“…Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to…”
Get full text

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study by Sunami, Kazutaka, Suzuki, Kenshi, Ri, Masaki, Matsumoto, Morio, Shimazaki, Chihiro, Asaoku, Hideki, Shibayama, Hirohiko, Ishizawa, Kenichi, Takamatsu, Hiroyuki, Ikeda, Takashi, Maruyama, Dai, Kaneko, Hitomi, Uchiyama, Michihiro, Kiguchi, Toru, Iyama, Satoshi, Murakami, Hirokazu, Takahashi, Keishiro, Tada, Keisuke, Macé, Sandrine, Guillemin‐Paveau, Hélène, Iida, Shinsuke

“…Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm,…”
Get full text

A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models by Tomita, Urara, Ishimoto, Yoko, Ri, Masaki, Kawase, Yumi, Hizukuri, Yoshiyuki, Maru, Chikako, Nanai, Kayoko, Nakamura, Ryuichi, Nakayama, Makiko, Oguchi-Oshima, Keiko, Sumi, Hiroyuki, Ohtsuka, Toshiaki, Iida, Shinsuke, Agatsuma, Toshinori

“…G-protein-coupled receptor class 5 member D (GPRC5D) is detected in malignant plasma cells in approximately 90% of patients diagnosed with multiple myeloma…”
Get full text

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort by Ri, Masaki, Suzuki, Kenshi, Ishida, Tadao, Kuroda, Junya, Tsukamoto, Taku, Teshima, Takanori, Goto, Hideki, Jackson, Carolyn C., Sun, Huabin, Pacaud, Lida, Fujikawa, Ei, Yeh, Tzu‐Min, Hatayama, Tomoyoshi, Aida, Kensuke, Sunagawa, Yoshihiro, Iida, Shinsuke

“…Chimeric antigen receptor (CAR) T cells targeting B‐cell maturation antigen have shown positive responses in patients with multiple myeloma (MM). The phase 2…”
Get full text

Periplocin and cardiac glycosides suppress the unfolded protein response by Tokugawa, Muneshige, Inoue, Yasumichi, Ishiuchi, Kan’ichiro, Kujirai, Chisane, Matsuno, Michiyo, Ri, Masaki, Itoh, Yuka, Miyajima, Chiharu, Morishita, Daisuke, Ohoka, Nobumichi, Iida, Shinsuke, Mizukami, Hajime, Makino, Toshiaki, Hayashi, Hidetoshi

“…The unfolded protein response (UPR) controls protein homeostasis through transcriptional and translational regulation. However, dysregulated UPR signaling has…”
Get full text

Clinical significance of tryptophan catabolism in Hodgkin lymphoma by Masaki, Ayako, Ishida, Takashi, Maeda, Yasuhiro, Ito, Asahi, Suzuki, Susumu, Narita, Tomoko, Kinoshita, Shiori, Takino, Hisashi, Yoshida, Takashi, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Inagaki, Hiroshi, Ueda, Ryuzo, Choi, Ilseung, Suehiro, Youko, Iida, Shinsuke

“…Indoleamine 2,3‐dioxygenase 1 (IDO) is an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway. The purpose of the present study was to…”
Get full text

Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay by Hagiwara, Shinya, Kusumoto, Shigeru, Inoue, Takako, Ogawa, Shintaro, Narita, Tomoko, Ito, Asahi, Ri, Masaki, Komatsu, Hirokazu, Suzuki, Takanori, Matsuura, Kentaro, Yagi, Shintaro, Kaneko, Atsushi, Aoyagi, Katsumi, Iida, Shinsuke, Tanaka, Yasuhito

“…Aims To prevent hepatitis B virus (HBV) reactivation‐related hepatitis, we examined the clinical usefulness of a highly sensitive HB core‐related antigen…”
Get full text

Recurrent pain attacks during romiplostim treatment in a patient with ITP carrying a heterozygous MEFV mutation by Kinoshita, Shiori, Komatsu, Hirokazu, Fujinami, Haruna, Yoshida, Takashi, Suzuki, Tomotaka, Narita, Tomoko, Ito, Asahi, Ri, Masaki, Kusumoto, Shigeru, Iida, Shinsuke

“…We report a case of recurrent pain attacks during romiplostim treatment in a woman with immune thrombocytopenia carrying a heterozygous MEFV mutation. Five…”
Get full text

A novel RARA–SNX15 fusion in PML–RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1) by Hirade, Kentaro, Kusumoto, Shigeru, Abe, Akihiro, Noritake, Hatsune, Ito, Asahi, Ri, Masaki, Komatsu, Hirokazu, Iida, Shinsuke, Yamamoto, Yukiya

“…Acute promyelocytic leukemia (APL) is characterized by a series of retinoic acid receptor (RAR) fusion genes that lead to the dysregulation of RAR signaling…”
Get full text

Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma by Totani, Haruhito, Shinjo, Keiko, Suzuki, Miho, Katsushima, Keisuke, Mase, Shoko, Masaki, Ayako, Ito, Asahi, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Ishida, Takashi, Inagaki, Hiroshi, Iida, Shinsuke, Kondo, Yutaka

“…Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasm. While ATL cells in peripheral blood (PB-ATL) are sensitive to anti-CC chemokine receptor…”
Get full text

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma by Yoshida, Takashi, Ri, Masaki, Kinoshita, Shiori, Narita, Tomoko, Totani, Haruhito, Ashour, Reham, Ito, Asahi, Kusumoto, Shigeru, Ishida, Takashi, Komatsu, Hirokazu, Iida, Shinsuke

“…Bortezomib (Btz) is an active agent used to treat multiple myeloma (MM). Not all patients who receive Btz-containing therapy show a favorable response…”
Get full text

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals by Masaki, Ayako, Ishida, Takashi, Suzuki, Susumu, Ito, Asahi, Narita, Tomoko, Kinoshita, Shiori, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Inagaki, Hiroshi, Ueda, Ryuzo, Iida, Shinsuke

“…Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk…”
Get full text

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma by Ri, Masaki, Suzuki, Kenshi, Iida, Shinsuke, Hatake, Kiyohiko, Chou, Takaaki, Taniwaki, Masafumi, Watanabe, Noriko, Tsukamoto, Tetsuji

“…Objective Multiple myeloma (MM) is the second most common hematological cancer. An attempt to treat MM using a topoisomerase I inhibitor was made based on our…”
Get full text

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma by Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Ishida, Tadao, Yamamoto, Junichi, Ito, Takumi, Futami, Muneyoshi, Ri, Masaki, Yasui, Hiroshi, Denda, Tamami, Tanaka, Yukihisa, Ota, Yasunori, Nojima, Masanori, Kamikubo, Yasuhiko, Gotoh, Noriko, Iida, Shinsuke, Handa, Hiroshi, Tojo, Arinobu

“…Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its…”
Get full text

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR by Takezako, Naoki, Shibayama, Hirohiko, Handa, Hiroshi, Hagiwara, Shotaro, Ozaki, Shuji, Suzuki, Kenshi, Kosugi, Hiroshi, Ri, Masaki, Sugiura, Isamu, Choi, Ilseung, Miyamoto, Toshihiro, Iida, Shinsuke

“…A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m 2 vs. twice-weekly Kd 20/27 mg/m 2 based on progression-free…”
Get full text

Symptoms and health-related quality of life in patients with newly diagnosed multiple myeloma: a multicenter prospective cohort study by Suzuki, Nana, Okuyama, Toru, Akechi, Tatsuo, Kusumoto, Shigeru, Ri, Masaki, Inagaki, Atsushi, Kayukawa, Satoshi, Yano, Hiroki, Yoshida, Takashi, Shiraga, Kazuhide, Hashimoto, Hiroya, Aiki, Sayo, Iida, Shinsuke

“…Abstract Objective Existing cross-sectional observational studies indicate that patients with multiple myeloma experience negative physical and psychological…”
Get full text

Design, Synthesis, and Biological Activity of Isosyringolin A by Kitahata, Shun, Chiba, Takuya, Yoshida, Takashi, Ri, Masaki, Iida, Shinsuke, Matsuda, Akira, Ichikawa, Satoshi

“…Isosyringolin A, which is an isomer of the proteasome-inhibiting natural product syringolin A, was designed and synthesized to develop analogues that are step…”
Get full text